Core Scientific (NASDAQ: CORZ) officer sells 10,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($231,497)
Net Sell
2 txns
Insider
DUCHENE TODD M
Role
See remarks
Sold
10,000 shs ($231K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,600 | $23.1244 | $222K |
| Sale | Common Stock | 400 | $23.7575 | $10K |
Holdings After Transaction:
Common Stock — 1,960,748 shares (Direct, null)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.66 to $23.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Key Figures
Shares sold: 10,000 shares
First tranche average price: $23.1244 per share
Second tranche average price: $23.7575 per share
+3 more
6 metrics
Shares sold
10,000 shares
Total Common Stock sold on May 18, 2026
First tranche average price
$23.1244 per share
9,600-share sale; trades from $22.66 to $23.62
Second tranche average price
$23.7575 per share
400-share sale; trades from $23.69 to $23.82
Post-transaction holdings
1,960,348 shares
Common Stock directly owned after May 18, 2026 sales
Trade date
May 18, 2026
Date of both open-market sales
Trading plan adoption date
December 5, 2025
Rule 10b5-1 trading plan adoption
Key Terms
Rule 10b5-1 trading plan, weighted average price, open-market sale, non-derivative
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.66 to $23.62, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
non-derivative financial
"transaction_type: non-derivative"
FAQ
Was the Core Scientific (CORZ) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025, indicating the sales were pre-arranged rather than newly decided.
What type of transactions did the Core Scientific (CORZ) officer execute?
The transactions were open-market sales of Common Stock, coded as “S” in the filing. Both entries are classified as non-derivative sales and are described as sales in open market or private transactions in the Form 4 data.